avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2023-13-4-253-262FJYEEHavk-1636Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESБиомаркеры развития нежелательных сердечно-сосудистых событий при заболеваниях почекBiomarkers of Adverse Cardiovascular Events in Kidney Diseasehttps://orcid.org/0000-0002-6129-0625КамышниковаЛ. А.KamyshnikovaL. A.

Людмила Александровна Камышникова

Белгород

Lyudmila A. Kamyshnikova

Belgorod

kamyshnikova@bsu.edu.ruhttps://orcid.org/0000-0003-2650-1738ГорбачевскаяК. С.GorbachevskayaK. S.

Белгород

Belgorod

https://orcid.org/0000-0002-6395-1626ЕфремоваО. А.EfremovaO. A.

Белгород

Belgorod

https://orcid.org/0000-0002-5308-8072ОболонковаН. И.ObolonkovaN. I.

Белгород

Belgorod 

https://orcid.org/0000-0001-7961-4352БолховитинаО. А.BolkhovitinaO. A.

Белгород

Belgorod

Белгородский государственный национальный исследовательский университетРоссияBelgorod State National Research UniversityRussian Federation202316082023134253262Copyright © Камышникова Л.А., Горбачевская К.С., Ефремова О.А., Оболонкова Н.И., Болховитина О.А., 20232023Камышникова Л.А., Горбачевская К.С., Ефремова О.А., Оболонкова Н.И., Болховитина О.А.Kamyshnikova L.A., Gorbachevskaya K.S., Efremova O.A., Obolonkova N.I., Bolkhovitina O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/1636

В обзоре представлена информация по анализу научно-исследовательских сведений в отечественных и международных источниках литературы о факторах риска и биомаркерах развития неблагоприятных сердечно-сосудистых событий у пациентов с хронической болезнью почек и острым повреждением почек. Исследования биомаркеров имеют важное значение, особенно на ранних стадиях хронической болезни почек, когда профилактические и лечебные мероприятия работают более эффективно. В обзоре рассматриваются такие предикторы сердечно-сосудистых событий при хронической болезни почек как биомаркеры: окислительного стресса (малоновый диальдегид, ишемически-модифицированный альбумин; супероксид дисмутаза), воспаления (интерлейкин-6, интерлейкин-18), острого повреждения почек (молекула повреждения почек 1; нейтрофильный желатиназа-ассоциированный липокалин), кардиоспецифические биомаркеры (высокочувствительный тропонин) и циркулирующие микрорибонуклеиновые кислоты: 133а и 21, а также обсуждаются перспективы дальнейшего изучения биомаркеров. Отдельный акцент сделан на необходимости установления пороговых значений для различных биомаркеров при хронической болезни почек в зависимости от степени снижения функции почек, что позволит эффективно использовать эти показатели в клинической практике сердечно-сосудистых заболеваний, поскольку обычные референсные значения, используемые в общей популяции, будут выше при заболеваниях почек. В настоящее время известны референсные значения для тропонина и натрийуретических пептидов, которые в популяции с хронической болезни почек не достаточно изучены, по сравнению с общей популяцией.

Based on domestic and international literature the review refers to the analysis of the research data on risk factors and biomarkers for the development of adverse cardiovascular events in patients with chronic kidney disease and acute kidney injury. Biomarker studies are important, especially in the early stages of chronic kidney disease, that is, in patients with creatinine clearance above 60 ml/min/1.73 m2, when preventive and therapeutic measures work more effectively. Among the potential predictors of adverse cardiovascular events, the biomarkers related to the following pathological processes (conditions) should be noted: oxidative stress (malondialdehyde, ischemic-modified albumin; superoxide dismutase), inflammation (interleukin-6, interleukin-18), acute kidney injury (kidney injury molecule 1; neutrophil gelatinase-associated lipocalin), cardiospecific biomarkers (highly sensitive troponin) and circulating microribonucleic acids (specific miRNA-133a, miRNA-21), as well as the prospects for further study of some biomarkers in cardionephrology are discussed. A separate emphasis is placed on the need to establish threshold values for various molecules in chronic kidney disease, depending on the degree of decline in kidney function, which will allow these indicators to be effectively used in clinical practice as diagnostic and prognostic biomarkers for cardiovascular diseases, since their usual reference values are used in the general population, will be higher in kidney disease. Currently, only for troponin and natriuretic peptides, certain reference values are established, which are less clear-cut in the population with chronic kidney disease than in the general population, and for all other biomarkers, cut-off values are not yet known.

хроническая болезнь почекострое повреждение почекпредикторысердечно-сосудистая системабиомаркерыchronic kidney diseaseacute kidney injurypredictorscardiovascular systembiomarkersReferencesZhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev. Cardiovasc. Med. 2022; 23(2): 73. doi: 10.31083/j.rcm2302073.Zhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev. Cardiovasc. Med. 2022; 23(2): 73. doi: 10.31083/j.rcm2302073.Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease. 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395: 709-733. doi: 10.1016/S0140-6736(20)30045-3.Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease. 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395: 709-733. doi: 10.1016/S0140-6736(20)30045-3.Di Lullo L, Gorini A, Russo D. et al. Left ventricular hypertrophy in chronic kidney disease patients: From Pathophysiology to treatment. Cardiorenal Med. 2015; 5: 254-266. doi: 10.1159/000435838.Di Lullo L, Gorini A, Russo D. et al. Left ventricular hypertrophy in chronic kidney disease patients: From Pathophysiology to treatment. Cardiorenal Med. 2015; 5: 254-266. doi: 10.1159/000435838.House A.A., Wanner C., Sarnak M.J. et al. Heart failure in chronic kidney disease: conclusions from a kidney disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019; 95: 1304-1317. DOI: 10.1016/j.kint.2019.02.022.House A.A., Wanner C., Sarnak M.J. et al. Heart failure in chronic kidney disease: conclusions from a kidney disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019; 95: 1304-1317. DOI: 10.1016/j.kint.2019.02.022.Segall L, Nistor I, Covic A. Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. Biomed Res. Int. 2014; 2014: 21. doi: I: 10.1155/2014/937398.Segall L, Nistor I, Covic A. Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. Biomed Res. Int. 2014; 2014: 21. doi: I: 10.1155/2014/937398.Romero-Gonzаlez G., Ravassa S., Gonzаlez O. et al. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrologia (English Edition). 2020; 40(3): 223-236. doi: 10.1016/j.nefroe.2020.06.006.Romero-Gonzаlez G., Ravassa S., Gonzаlez O. et al. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrologia (English Edition). 2020; 40(3): 223-236. doi: 10.1016/j.nefroe.2020.06.006.Tawfik A.M., Tawfik H.M. Nontraditional risk factors in chronic kidney disease: correlation between creatinine clearance, Framingham risk score, endothelial dysfunction, and inflammation. Egypt J Intern Med. 2022; 34: 29. doi: 10.1186/s43162-022-00110-2.Tawfik A.M., Tawfik H.M. Nontraditional risk factors in chronic kidney disease: correlation between creatinine clearance, Framingham risk score, endothelial dysfunction, and inflammation. Egypt J Intern Med. 2022; 34: 29. doi: 10.1186/s43162-022-00110-2.Stopic B., Medic-Brkic B., Savic-Vujovic K. et al. Biomarkers and Predictors of Adverse Cardiovascular Events in Different Stages of Chronic Kidney Disease. Dose-Response. 2022; 20(3). doi:10.1177/15593258221127568.Stopic B., Medic-Brkic B., Savic-Vujovic K. et al. Biomarkers and Predictors of Adverse Cardiovascular Events in Different Stages of Chronic Kidney Disease. Dose-Response. 2022; 20(3). doi:10.1177/15593258221127568.Efremova O.A., Kamyshnikova L.A., Obolonkova N.I., et al. Mechanisms of Development of Heart Failure in Chronic Kidney Disease. Challenges in Modern Medicine. 2022; 45(3): 237–252. doi: 10.52575/2687-0940-2022-45-3-237-252.Efremova O.A., Kamyshnikova L.A., Obolonkova N.I., et al. Mechanisms of Development of Heart Failure in Chronic Kidney Disease. Challenges in Modern Medicine. 2022; 45(3): 237–252. doi: 10.52575/2687-0940-2022-45-3-237-252.Kong AS.-Y., Lai K.S., Hee C.-W. et al. Oxidative Stress Parameters as Biomarkers of Cardiovascular Disease towards the Development and Progression. Antioxidants. 2022; 11(6): 1175. doi: 10.3390/antiox11061175.Kong AS.-Y., Lai K.S., Hee C.-W. et al. Oxidative Stress Parameters as Biomarkers of Cardiovascular Disease towards the Development and Progression. Antioxidants. 2022; 11(6): 1175. doi: 10.3390/antiox11061175.Afshinnia F., Zeng L., Byun, J. et al. Michigan Kidney Translational Core, C.I.G. Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease. Am. J. Nephrol. 2017;46:73–81. doi: 10.1159/000477766.Afshinnia F., Zeng L., Byun, J. et al. Michigan Kidney Translational Core, C.I.G. Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease. Am. J. Nephrol. 2017;46:73–81. doi: 10.1159/000477766.Ighodaro O.M., Akinloye O.A. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alexandria J Med. 2018;54(4):287-293. doi: 10.1016/j.ajme.2017.09.001.Ighodaro O.M., Akinloye O.A. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alexandria J Med. 2018;54(4):287-293. doi: 10.1016/j.ajme.2017.09.001.Tsai Y.-T., Yeh H.-Y., Chao Ch.-T., et al. Superoxide Dismutase 2 (SOD2) in Vascular Calcification: A Focus on Vascular Smooth Muscle Cells, Calcification Pathogenesis, and Therapeutic Strategies Oxidative Medicine and Cellular Longevity. 2021;2021:6675548. doi: 10.1155/2021/6675548Tsai Y.-T., Yeh H.-Y., Chao Ch.-T., et al. Superoxide Dismutase 2 (SOD2) in Vascular Calcification: A Focus on Vascular Smooth Muscle Cells, Calcification Pathogenesis, and Therapeutic Strategies Oxidative Medicine and Cellular Longevity. 2021;2021:6675548. doi: 10.1155/2021/6675548Nepal M., Jaisawal S., Guragain M., et al. Ischemic Modified Albumin (IMA) As a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions. J Cardiovascular Disease Res. 2017;8(4):112-116. doi: 10.1155/2021/9945424. 1Nepal M., Jaisawal S., Guragain M., et al. Ischemic Modified Albumin (IMA) As a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions. J Cardiovascular Disease Res. 2017;8(4):112-116. doi: 10.1155/2021/9945424. 1Ozkurt S., Ozcan O., Dogan I. Assessment of Ischemia Modified Albumin as a Marker of Oxidative Stress in Chronic Kidney Disease. Saudi J Kidney Dis Transpl. 2021;(4): 1006-1012.Ozkurt S., Ozcan O., Dogan I. Assessment of Ischemia Modified Albumin as a Marker of Oxidative Stress in Chronic Kidney Disease. Saudi J Kidney Dis Transpl. 2021;(4): 1006-1012.Wang, Y., Liang, Y., Zhao, W. et al. Circulating miRNA-21 as a diagnostic biomarker in elderly patients with type 2 cardiorenal syndrome. Sci Rep. 2020;10:4894. doi:10.1038/s41598-020-61836-zISI.Wang, Y., Liang, Y., Zhao, W. et al. Circulating miRNA-21 as a diagnostic biomarker in elderly patients with type 2 cardiorenal syndrome. Sci Rep. 2020;10:4894. doi:10.1038/s41598-020-61836-zISI.Freitas I.A., Lima N.A., Silva G.B.D.Jr et al. Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery disease. Rev Port Cardiol. 2020;39(11):667-672. doi: DOI: 10.1016/j.repc.2020.05.010.Freitas I.A., Lima N.A., Silva G.B.D.Jr et al. Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery disease. Rev Port Cardiol. 2020;39(11):667-672. doi: DOI: 10.1016/j.repc.2020.05.010.Li C., Zhang Z., Peng Y., et al. Plasma neutrophil gelatinase-associated lipocalin levels are associated with the presence and severity of coronary heart disease. PLoS One. 2019;14(8):e0220841. doi: 10.1371/journal.pone.0220841.Li C., Zhang Z., Peng Y., et al. Plasma neutrophil gelatinase-associated lipocalin levels are associated with the presence and severity of coronary heart disease. PLoS One. 2019;14(8):e0220841. doi: 10.1371/journal.pone.0220841.Medić B., Rovčanin B., Basta Jovanović G. et al. Kidney Injury Molecule-1 and Cardiovascular Diseases: From Basic Science to Clinical Practice. BioMed Res Int. 2015;2015:854070. doi: 10.1155/2015/854070.Medić B., Rovčanin B., Basta Jovanović G. et al. Kidney Injury Molecule-1 and Cardiovascular Diseases: From Basic Science to Clinical Practice. BioMed Res Int. 2015;2015:854070. doi: 10.1155/2015/854070.Hasegawa M., Ishii J., Kitagawa F., et al. Plasma Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Cardiovascular Events in Patients with Chronic Kidney Disease. BioMed Res Int. 2016;2016:8761475. doi: 10.1155/2016/8761475.Hasegawa M., Ishii J., Kitagawa F., et al. Plasma Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Cardiovascular Events in Patients with Chronic Kidney Disease. BioMed Res Int. 2016;2016:8761475. doi: 10.1155/2016/8761475.Liu K.D., Yang W., Go A.S., et al. Urine Neutrophil GelatinaseAssociated Lipocalin and Risk of Cardiovascular Disease and Death in CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2015;65(2):267-274. doi: 10.1053/j.ajkd.2014.07.025.Liu K.D., Yang W., Go A.S., et al. Urine Neutrophil GelatinaseAssociated Lipocalin and Risk of Cardiovascular Disease and Death in CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2015;65(2):267-274. doi: 10.1053/j.ajkd.2014.07.025.Park M., Hsu C.Y., Go A.S., et al. Urine kidney injury biomarkers and risks of cardiovascular disease events and all-cause death: The CRIC Study. Clin J Am Soc Nephrol. 2017;12(5):761-771. doi: 10.2215/CJN.08560816.Park M., Hsu C.Y., Go A.S., et al. Urine kidney injury biomarkers and risks of cardiovascular disease events and all-cause death: The CRIC Study. Clin J Am Soc Nephrol. 2017;12(5):761-771. doi: 10.2215/CJN.08560816.Feldreich T., Nowak C., Fall T., et al. Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease. J Nephrol. 2019;32(1):111-119. doi: 10.1007/s40620-018-0556-5.Feldreich T., Nowak C., Fall T., et al. Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease. J Nephrol. 2019;32(1):111-119. doi: 10.1007/s40620-018-0556-5.Ledwoch, J., Krauth, A., Kraxenberger, J. et al. Accuracy of highsensitive troponin depending on renal function for clinical outcome prediction in patients with acute heart failure. Heart Vessels. 2022;37;69–76. doi:10.1007/s00380-021-01890-3.Ledwoch, J., Krauth, A., Kraxenberger, J. et al. Accuracy of highsensitive troponin depending on renal function for clinical outcome prediction in patients with acute heart failure. Heart Vessels. 2022;37;69–76. doi:10.1007/s00380-021-01890-3.Michos E.D., Wilson L.M., Yeh H.C., et al. Рrognostic Value of Cardiac Troponin in Patients With Chronic Kidney Disease Without Suspected Acute Coronary Syndrome. Ann Intern Med. 2014;161(7):491-501. doi: 10.7326/M14-0743.Michos E.D., Wilson L.M., Yeh H.C., et al. Рrognostic Value of Cardiac Troponin in Patients With Chronic Kidney Disease Without Suspected Acute Coronary Syndrome. Ann Intern Med. 2014;161(7):491-501. doi: 10.7326/M14-0743.Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4103. doi: 10.15829/15604071-2020-4103.Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Society of Cardiology 2020. Russian Journal of Cardiology. 2020;25(11):4103. https://doi.org/10.15829/1560-40712020-4103 [In Russian].Kampmann J., Heaf J., Backer Mogensen C., et al. Troponin Cut-Offs for Acute Myocardial Infarction in Patients with Impaired Renal Function—A Systematic Review and Meta-Analysis. Diagnostics. 2022;12:276. doi:10.3390/diagnostics12020276.Kampmann J., Heaf J., Backer Mogensen C., et al. Troponin Cut-Offs for Acute Myocardial Infarction in Patients with Impaired Renal Function—A Systematic Review and Meta-Analysis. Diagnostics. 2022;12:276. doi:10.3390/diagnostics12020276.Niizuma S., Iwanaga Y., Yahata T. et al. Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease. Front Cardiovasc Med. 2017;4:10. doi: 10.3389/fcvm.2017.00010.Niizuma S., Iwanaga Y., Yahata T. et al. Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease. Front Cardiovasc Med. 2017;4:10. doi: 10.3389/fcvm.2017.00010.Goldsmith S.R. Arginine Vasopressin Antagonism in Heart Failure: Current Status and Possible New Directions. J. Cardiol. 2019;74:49– 52. doi: 10.1016/j.jjcc.2019.03.001.Goldsmith S.R. Arginine Vasopressin Antagonism in Heart Failure: Current Status and Possible New Directions. J. Cardiol. 2019;74:49– 52. doi: 10.1016/j.jjcc.2019.03.001.Schill F., Timpka S., Nilsson P.M., et al. Copeptin as a Predictive Marker of Incident Heart Failure. ESC Heart Fail. 2021;8:3180-3188. doi: 10.1002/ehf2.13439.Schill F., Timpka S., Nilsson P.M., et al. Copeptin as a Predictive Marker of Incident Heart Failure. ESC Heart Fail. 2021;8:3180-3188. doi: 10.1002/ehf2.13439.Jankowich M., Choudhary G. Endothelin-1 levels and cardiovascular events. Trends Cardiovasc Med. 2020 Jan;30(1):1-8. doi: 10.1016/j.tcm.2019.01.007.Jankowich M., Choudhary G. Endothelin-1 levels and cardiovascular events. Trends Cardiovasc Med. 2020 Jan;30(1):1-8. doi: 10.1016/j.tcm.2019.01.007.Kocyigit I., Eroglu E., Kaynar A.S. et al. The association of endothelin-1 levels with renal survival in polycystic kidney disease patients. J Nephrol. 2019;32:83–91. doi: 10.1007/s40620-018-0514-2.Kocyigit I., Eroglu E., Kaynar A.S. et al. The association of endothelin-1 levels with renal survival in polycystic kidney disease patients. J Nephrol. 2019;32:83–91. doi: 10.1007/s40620-018-0514-2.Batra G., Ghukasyan Lakic T., Lindbäck J. et al. STABILITY Investigators. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiol. 2021;6(12):1440-1445. doi: 10.1001/jamacardio.2021.3079.Batra G., Ghukasyan Lakic T., Lindbäck J. et al. STABILITY Investigators. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiol. 2021;6(12):1440-1445. doi: 10.1001/jamacardio.2021.3079.Ефремова Е.В., Шутов А.М. Прогностические биомаркеры при хроническом кардиоренальном синдроме у пациентов старшей возрастной группы. Нефрология и диализ. 2022. 24(2):357-365. doi: 10.28996/2618-9801-2022-2-357-365Efremova E.V., Shutov A.M. Predictive biomarkers in elderly patients with chronic cardiorenal syndrome. Nephrologу and Dialуsis. 2022;24(2):357-365. Russian. doi: 10.28996/2618-9801-2022-2-357-365Schunk S.J., Triem S., Schmit D., et al. Interleukin-1α Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease. Circulation. 2021;144(11):893-908. doi: 10.1161/CIRCULATIONAHA.121.053547.Schunk S.J., Triem S., Schmit D., et al. Interleukin-1α Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease. Circulation. 2021;144(11):893-908. doi: 10.1161/CIRCULATIONAHA.121.053547.Formanowicz D., Wanic-Kossowska M., Pawliczak E., Radom M., Formanowicz P. Usefulness of serum interleukin-18 in predicting cardiovascularmortality in patients with chronic kidney disease — systems and clinical approach. Sci Rep. 2015;5:18332. doi: 10.1038/srep18332.Formanowicz D., Wanic-Kossowska M., Pawliczak E., Radom M., Formanowicz P. Usefulness of serum interleukin-18 in predicting cardiovascularmortality in patients with chronic kidney disease — systems and clinical approach. Sci Rep. 2015;5:18332. doi: 10.1038/srep18332.Дзгоева Ф.У., Ремизов О.В., Голоева В.Г. и др. Обновленные механизмы кальцификации сердечно-сосудистой системы и ее коррекции при хронической болезни почек. Нефрология 2020;24(5):18-28. doi: 10.36485/1561-6274-2020-24-5-18-28.Dzgoeva F.U., Remizov O.V., Goloeva V.G. et al. Updated mechanisms of calcification of cardiovascular system and its correction in chronic kidney disease. Nephrology 2020;24(5):18-28 doi: 10.36485/15616274-2020-24-5-18-28 [In Russian].Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD); Kidney Int Suppl. 2017;7:1-59. doi: 10.1016/j.kisu.2017.04.001.Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD); Kidney Int Suppl. 2017;7:1-59. doi: 10.1016/j.kisu.2017.04.001.Daisuke S., Noriaki T., Motoko T. et al. Associations Between Corrected Serum Calcium and Phosphorus Levels and Outcome in Dialysis Patients in the Kumamoto Prefecture. Hemodial Int. 2020; 24(2):202–211. doi: 10.1111/hdi.1282.Daisuke S., Noriaki T., Motoko T. et al. Associations Between Corrected Serum Calcium and Phosphorus Levels and Outcome in Dialysis Patients in the Kumamoto Prefecture. Hemodial Int. 2020; 24(2):202–211. doi: 10.1111/hdi.1282.Raikou V.D. Serum phosphate and chronic kidney and cardiovascular disease: Phosphorus potential implications in general population. World J Nephrol. 2021;10(5):76-87. doi: 10.5527/wjn.v10.i5.76.Raikou V.D. Serum phosphate and chronic kidney and cardiovascular disease: Phosphorus potential implications in general population. World J Nephrol. 2021;10(5):76-87. doi: 10.5527/wjn.v10.i5.76.Takashi Y., Wakino S., Minakuchi H. et al. Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients. J Bone Miner Metab. 2020;38(1):70–77. doi: 10.1007/s00774-019-010277.Takashi Y., Wakino S., Minakuchi H. et al. Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients. J Bone Miner Metab. 2020;38(1):70–77. doi: 10.1007/s00774-019-010277.24. Waziri B., Duarte R., Naicker S. Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD): Current Perspectives. Int J Nephrol Renovasc Dis. 2019;12:263-276. doi:10.2147/IJNRD.S191156.24. Waziri B., Duarte R., Naicker S. Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD): Current Perspectives. Int J Nephrol Renovasc Dis. 2019;12:263-276. doi:10.2147/IJNRD.S191156.Bäck M., Aranyi T., Cancela M.L., et al. Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet. Front Cardiovasc Med. 2019;5:196. doi: 10.3389/fcvm.2018.00196.Bäck M., Aranyi T., Cancela M.L., et al. Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet. Front Cardiovasc Med. 2019;5:196. doi: 10.3389/fcvm.2018.00196.Demir P., Erdenen F., Aral H., et al. Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease. J Clin Lab Anal. 2016;30(6):811-817. doi: 10.1002/jcla.21941.Demir P., Erdenen F., Aral H., et al. Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease. J Clin Lab Anal. 2016;30(6):811-817. doi: 10.1002/jcla.21941.Boutin L, Dépret F, Gayat E, Legrand M, Chadjichristos CE. Galectin-3 in Kidney Diseases: From an Old Protein to a New Therapeutic Target. International Journal of Molecular Sciences. 2022;23(6):3124. doi: 10.3390/ijms23063124.Boutin L, Dépret F, Gayat E, Legrand M, Chadjichristos CE. Galectin-3 in Kidney Diseases: From an Old Protein to a New Therapeutic Target. International Journal of Molecular Sciences. 2022;23(6):3124. doi: 10.3390/ijms23063124.Hara A., Niwa M., Noguchi K. et al. Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules. 2020;10:389. doi: 10.3390/biom10030389.Hara A., Niwa M., Noguchi K. et al. Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules. 2020;10:389. doi: 10.3390/biom10030389.Li M., Yuan Y., Guo K. et al. Value of Galectin-3 in Acute Myocardial Infarction. Am J Cardiovasc Drugs. 2020;20:333–342. doi:10.1007/s40256-019-00387-9.Li M., Yuan Y., Guo K. et al. Value of Galectin-3 in Acute Myocardial Infarction. Am J Cardiovasc Drugs. 2020;20:333–342. doi:10.1007/s40256-019-00387-9.Wyler Von Ballmoos M., Likosky D.S., Rezaee M.; et al. Galectin-3 Is Associated with Acute Kidney Injury after Cardiac Surgery. BMC Nephrol. 2018;19:280. doi: 10.1186/s12882-018-1093-0.Wyler Von Ballmoos M., Likosky D.S., Rezaee M.; et al. Galectin-3 Is Associated with Acute Kidney Injury after Cardiac Surgery. BMC Nephrol. 2018;19:280. doi: 10.1186/s12882-018-1093-0.Tan K.C.B., Cheung, C.L., Lee, A.C.H. et al. Galectin-3 Is Independently Associated with Progression of Nephropathy in Type 2 Diabetes Mellitus. Diabetologia. 2018;61:1212–1219. doi: 10.1007/s00125-0184552-z.Tan K.C.B., Cheung, C.L., Lee, A.C.H. et al. Galectin-3 Is Independently Associated with Progression of Nephropathy in Type 2 Diabetes Mellitus. Diabetologia. 2018;61:1212–1219. doi: 10.1007/s00125-0184552-z.Boutin L., Legrand M., Sadoune M et al. Galectin-3 Is Associated with Major Adverse Kidney Events and Death after ICU Admission. Crit. Care. 2022;26:13. doi: 10.1186/s13054-021-03878-x.Boutin L., Legrand M., Sadoune M et al. Galectin-3 Is Associated with Major Adverse Kidney Events and Death after ICU Admission. Crit. Care. 2022;26:13. doi: 10.1186/s13054-021-03878-x.Desmedt V., Desmedt S., Delanghe J.R., Speeckaert R., Speeckaert M.M. Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander? Am. J. Nephrol. 2016;43:305–317. doi: 10.1159/000446376.Desmedt V., Desmedt S., Delanghe J.R., Speeckaert R., Speeckaert M.M. Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander? Am. J. Nephrol. 2016;43:305–317. doi: 10.1159/000446376.Hara A., Niwa M., Kanayama T. et al. Galectin-3: A Potential Prognostic and Diagnostic Marker for Heart Disease and Detection of Early Stage Pathology. Biomolecules. 2020;10:1277. doi: 10.3390/biom10091277.Hara A., Niwa M., Kanayama T. et al. Galectin-3: A Potential Prognostic and Diagnostic Marker for Heart Disease and Detection of Early Stage Pathology. Biomolecules. 2020;10:1277. doi: 10.3390/biom10091277.Prudhomme M., Coutrot M., Michel T. et al. Acute Kidney Injury Induces Remote Cardiac Damage and Dysfunction Through the Galectin-3 Pathway. JACC: Basic Transl. Sci. 2019;4:717–732. doi: 10.1016/j.jacbts.2019.06.005.Prudhomme M., Coutrot M., Michel T. et al. Acute Kidney Injury Induces Remote Cardiac Damage and Dysfunction Through the Galectin-3 Pathway. JACC: Basic Transl. Sci. 2019;4:717–732. doi: 10.1016/j.jacbts.2019.06.005.Kousios A., Kouis P., Panayiotou A.G. Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease: A Systematic Review. Int. J. Nephrol. 2016;2016:9498013. doi: 10.1155/2016/9498013.Kousios A., Kouis P., Panayiotou A.G. Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease: A Systematic Review. Int. J. Nephrol. 2016;2016:9498013. doi: 10.1155/2016/9498013.Ravarotto V., Simioni F., Pagnin E. et al. Oxidative stress—chronic kidney disease—cardiovascular disease: A vicious circle. Life Sci. 2018;210:125–131. doi: 10.1016/j.lfs.2018.08.067.Ravarotto V., Simioni F., Pagnin E. et al. Oxidative stress—chronic kidney disease—cardiovascular disease: A vicious circle. Life Sci. 2018;210:125–131. doi: 10.1016/j.lfs.2018.08.067.Гилязова ИР, Хасанова ГМ, Иванова ЕА, и др. Исследование профилей экспрессии экзосомальных микроРНК-126 и микроРНК-218 у пациентов с геморрагической лихорадкой с почечным синдромом (ГЛПС). Научные результаты биомедицинских исследований. 2022;8(4):424-438. doi: 10.18413/26586533-2022-8-4-0-2.Gilyazova IR, Khasanova GM, Ivanova EA, et al. Study of the exosomal microRNA-126 and microRNA-218 expression profiles in patients with hemorrhagic fever with renal syndrome (HFRS). Research Results in Biomedicine. 2022;8(4):424-438. Russian. doi: 10.18413/2658-6533-2022-8-4-0-2Silva D.C.P., Carneiro F.D., Almeida K.C. et al. Role of miRNAs on the Pathophysiology of Cardiovascular Diseases. Arq Bras Cardiol. 2018;11(05):738-746. doi: 10.5935/abc.20180215.Silva D.C.P., Carneiro F.D., Almeida K.C. et al. Role of miRNAs on the Pathophysiology of Cardiovascular Diseases. Arq Bras Cardiol. 2018;11(05):738-746. doi: 10.5935/abc.20180215.Romaine S.P.R., Tomaszewski M., Condorelli G. et al. MicroRNAs in cardiovasculare disease: an introduction for clinicians. Heart. 2015;101(12):921-928. doi: 10.1136/heartjnl-2013-305402.Romaine S.P.R., Tomaszewski M., Condorelli G. et al. MicroRNAs in cardiovasculare disease: an introduction for clinicians. Heart. 2015;101(12):921-928. doi: 10.1136/heartjnl-2013-305402.Eyileten C., Wicik Z., De Rosa S. et al. MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Stroke—A Comprehensive Review and Bioinformatic Analysis. Cells. 2018;7(12):249. doi: 10.3390/cells7120249.Eyileten C., Wicik Z., De Rosa S. et al. MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Stroke—A Comprehensive Review and Bioinformatic Analysis. Cells. 2018;7(12):249. doi: 10.3390/cells7120249.Elmadbouly A.A., Hamdy R.M., Elsaeed A.M. et al. The Plasma Level of miRNA-133a as a Novel Biomarker for Prediction of Left Ventricular Hypertrophy and Dysfunction in Hemodialysis Patients. Am J Biochem. 2017;7(5):91-99. doi: 10.5923/j.ajb.20170705.02.Elmadbouly A.A., Hamdy R.M., Elsaeed A.M. et al. The Plasma Level of miRNA-133a as a Novel Biomarker for Prediction of Left Ventricular Hypertrophy and Dysfunction in Hemodialysis Patients. Am J Biochem. 2017;7(5):91-99. doi: 10.5923/j.ajb.20170705.02.Buliga-Finis O.N., Ouatu A., Tanase D.M., et al. Managing Anemia: Point of Convergence for Heart Failure and Chronic Kidney Disease? Life. 2023;13(6):1311. doi: 10.3390/life13061311Buliga-Finis O.N., Ouatu A., Tanase D.M., et al. Managing Anemia: Point of Convergence for Heart Failure and Chronic Kidney Disease? Life. 2023;13(6):1311. doi: 10.3390/life13061311

The authors declare that there are no conflicts of interest present.